Answers are grounded in this paper and cite their sources.
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer’s disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6–12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.
No takes yet. Share an insight, caveat, or question.
Farlow et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: